

Bertha K Madras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/464805/publications.pdf>

Version: 2024-02-01

110
papers

6,997
citations

66343

42
h-index

62596

80
g-index

110
all docs

110
docs citations

110
times ranked

6089
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine transporter density in patients with attention deficit hyperactivity disorder. <i>Lancet</i> , The, 1999, 354, 2132-2133.	13.7	590
2	Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later. <i>Drug and Alcohol Dependence</i> , 2009, 99, 280-295.	3.2	579
3	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) Analogues: A Promising Class of Monoamine Uptake Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1420-1432.	6.4	349
4	The Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2005, 57, 1397-1409.	1.3	329
5	Modafinil Occupies Dopamine and Norepinephrine Transporters in Vivo and Modulates the Transporters and Trace Amine Activity in Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 561-569.	2.5	304
6	Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. <i>Synapse</i> , 1991, 9, 43-49.	1.2	230
7	PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate. <i>American Journal of Psychiatry</i> , 2006, 163, 387-395.	7.2	188
8	In Vivo Neuroreceptor Imaging in Attention-Deficit/Hyperactivity Disorder: A Focus on The Dopamine Transporter. <i>Biological Psychiatry</i> , 2005, 57, 1293-1300.	1.3	166
9	Relevance of free tryptophan in serum to tissue tryptophan concentrations. <i>Metabolism: Clinical and Experimental</i> , 1974, 23, 1107-1116.	3.4	155
10	MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. <i>Psychopharmacology</i> , 2006, 189, 489-503.	3.1	145
11	Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. <i>Behavioural Brain Research</i> , 2002, 130, 79-83.	2.2	140
12	Further Evidence of Dopamine Transporter Dysregulation in ADHD: A Controlled PET Imaging Study Using Altropane. <i>Biological Psychiatry</i> , 2007, 62, 1059-1061.	1.3	139
13	Repetitive Behaviors in Monkeys Are Linked to Specific Striatal Activation Patterns. <i>Journal of Neuroscience</i> , 2004, 24, 7557-7565.	3.6	128
14	Melatonin promotes sleep in three species of diurnal nonhuman primates. <i>Physiology and Behavior</i> , 2002, 75, 523-529.	2.1	123
15	Office of National Drug Control Policy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1187, 370-402.	3.8	119
16	Primate Trace Amine Receptor 1 Modulation by the Dopamine Transporter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 983-994.	2.5	106
17	Rapid detection of Parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters. , 1998, 29, 128-141.		104
18	Rhesus Monkey Trace Amine-Associated Receptor 1 Signaling: Enhancement by Monoamine Transporters and Attenuation by the D2 Autoreceptor in Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 116-127.	2.5	103

#	ARTICLE	IF	CITATIONS
19	Serum tryptophan level after carbohydrate ingestion: Selective decline in non-albumin-bound tryptophan coincident with reduction in serum free fatty acids. <i>Life Sciences</i> , 1973, 12, 57-64.	4.3	99
20	The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). <i>Behavioural Brain Research</i> , 2002, 130, 57-63.	2.2	99
21	Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brain. <i>Synapse</i> , 1990, 6, 189-195.	1.2	93
22	2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: Potent Non-Nitrogen Inhibitors of Monoamine Transporters. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 2661-2673.	6.4	92
23	Cerebellar Vermis Involvement in Cocaine-Related Behaviors. <i>Neuropsychopharmacology</i> , 2006, 31, 1318-1326.	5.4	90
24	Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System. <i>NAM Perspectives</i> , 2020, 2020, .	2.9	90
25	The Surge of Opioid Use, Addiction, and Overdoses. <i>JAMA Psychiatry</i> , 2017, 74, 441.	11.0	89
26	The Discovery of an Unusually Selective and Novel Cocaine Analog: Difluoropine. Synthesis and Inhibition of Binding at Cocaine Recognition Sites. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 2001-2010.	6.4	88
27	History of the Discovery of the Antipsychotic Dopamine D2 Receptor: A Basis for the Dopamine Hypothesis of Schizophrenia. <i>Journal of the History of the Neurosciences</i> , 2013, 22, 62-78.	0.9	85
28	Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. <i>Psychopharmacology</i> , 2001, 156, 79-85.	3.1	82
29	Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. <i>Molecular Brain Research</i> , 2001, 87, 124-143.	2.3	74
30	D1 and D2 Dopamine Receptors in Caudate-Putamen of Nonhuman Primates (<i>Macaca fascicularis</i>). <i>Journal of Neurochemistry</i> , 1988, 51, 934-943.	3.9	67
31	Distribution of cocaine recognition sites in monkey brain: I. In vitro autoradiography with [3H]CFT. <i>Synapse</i> , 1991, 9, 177-187.	1.2	65
32	Technepine: A high-affinity technetium probe to label the dopamine transporter in brain by SPECT imaging. , 1996, 22, 239-246.		64
33	A Technetium-99m SPECT Imaging Agent Which Targets the Dopamine Transporter in Primate Brain. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 1835-1844.	6.4	60
34	Nitrogen-based drugs are not essential for blockade of monoamine transporters. , 1996, 24, 340-348.		59
35	The President's Commission on Combating Drug Addiction and the Opioid Crisis: Origins and Recommendations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 943-945.	4.7	59
36	2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: Potent Non-Nitrogen Inhibitors of Monoamine Transporters. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2982-2991.	6.4	57

#	ARTICLE	IF	CITATIONS
37	[11C,127I] Altoprane: A highly selective ligand for PET imaging of dopamine transporter sites. Synapse, 2001, 39, 332-342.	1.2	57
38	Distribution of cocaine recognition sites in monkey brain: II. Ex vivo autoradiography with [3H]CFT and [125I]RTI-55. Synapse, 1992, 12, 99-111.	1.2	55
39	The Growing Problem of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences, 2016, 32, 1-18.	1.7	51
40	Synthesis and receptor binding of N-substituted tropane derivatives. High-affinity ligands for the cocaine receptor. Journal of Medicinal Chemistry, 1991, 34, 1728-1731.	6.4	50
41	Altoprane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. , 1998, 29, 116-127.		50
42	Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors. Biology of Sex Differences, 2020, 11, 8.	4.1	49
43	Cocaine accumulates in dopamine-rich regions of primate brain after I.V. Administration: Comparison with mazindol distribution. Synapse, 1994, 18, 261-275.	1.2	47
44	Pharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis. Trends in Pharmacological Sciences, 2018, 39, 995-998.	8.7	47
45	2-Carbomethoxy-3-(diarylmethoxy)-1 α H,5 β H-tropane Analogs: A Synthesis and Inhibition of Binding at the Dopamine Transporter and Comparison with Piperazines of the GBR Series. Journal of Medicinal Chemistry, 1996, 39, 371-379.	6.4	44
46	Functional Genomics of Attention-Deficit/Hyperactivity Disorder (ADHD) Risk Alleles on Dopamine Transporter Binding in ADHD and Healthy Control Subjects. Biological Psychiatry, 2013, 74, 84-89.	1.3	44
47	[3H]PNU-101958, a D4 dopamine receptor probe, accumulates in prefrontal cortex and hippocampus of non-human primate brain. Synapse, 2000, 37, 232-244.	1.2	43
48	Formation of respiratory 14CO2 from variously labeled forms of tryptophan-14C in intact and adrenalectomized rats. Archives of Biochemistry and Biophysics, 1968, 125, 829-836.	3.0	41
49	Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-1,3-diazol-4-yl conjugates of D-1 and D-2 receptor ligands. Journal of Medicinal Chemistry, 1991, 34, 3235-3241.	6.4	39
50	Receptor Regulation of Gene Expression of Axon Guidance Molecules: Implications for Adaptation. Molecular Pharmacology, 2006, 70, 71-77.	2.3	39
51	Prescription opioid abuse: challenges and opportunities for payers. American Journal of Managed Care, 2013, 19, 295-302.	1.1	39
52	Drug use among youth: National survey data support a common liability of all drug use. Preventive Medicine, 2018, 113, 68-73.	3.4	38
53	Synthesis of 6- and 7- Hydroxy-8-azabicyclo[3.2.1]octanes and Their Binding Affinity for the Dopamine and Serotonin Transporters. Journal of Medicinal Chemistry, 2001, 44, 2619-2635.	6.4	37
54	A Primate Model of Huntington'S Disease: Functional Neural Transplantation and Ct-Guided Stereotactic Procedures. Cell Transplantation, 1992, 1, 313-322.	2.5	36

#	ARTICLE	IF	CITATIONS
55	Altropane, a SPECT or PET imaging probe for dopamine neurons: I. dopamine transporter binding in primate brain. <i>Synapse</i> , 1998, 29, 93-104.	1.2	36
56	Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse. <i>JAMA Network Open</i> , 2019, 2, e1916015.	5.9	36
57	Altropane, a SPECT or PET imaging probe for dopamine neurons: II. distribution to dopamine-rich regions of primate brain. , 1998, 29, 105-115.		35
58	Synthesis and Evaluation of Dopamine and Serotonin Transporter Inhibition by Oxacyclic and Carbacyclic Analogues of Methylphenidate. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1538-1545.	6.4	35
59	Metabolism of $\hat{1}\pm$ -methyltryptophan. <i>Biochemical Pharmacology</i> , 1965, 14, 1499-1506.	4.4	34
60	Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of ^{11}C -CFT. , 1996, 24, 262-272.		33
61	Bicyclo[3.2.1]octanes: Synthesis and inhibition of binding at the dopamine and serotonin transporters. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 857-862.	2.2	30
62	Dopamine transporter-dependent induction of C-Fos in HEK cells. <i>Synapse</i> , 2002, 45, 52-65.	1.2	28
63	Ephrin/Eph receptor expression in brain of adult nonhuman primates: Implications for neuroadaptation. <i>Brain Research</i> , 2006, 1067, 67-77.	2.2	28
64	Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 570-585.	2.5	24
65	MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. <i>Journal of Psychopharmacology</i> , 2008, 22, 187-202.	4.0	24
66	Design and synthesis of an irreversible dopamine-sparing cocaine antagonist. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 3583-3591.	3.0	22
67	$\hat{1}$ "-Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons. <i>IScience</i> , 2020, 23, 100794.	4.1	22
68	Dopamine D1-D2 receptor heteromer expression in key brain regions of rat and higher species: Upregulation in rat striatum after cocaine administration. <i>Neurobiology of Disease</i> , 2020, 143, 105017.	4.4	22
69	3-Aryl-2-carbomethoxybicyclo[3.2.1]oct-2-enes inhibit WIN 35,428 binding potently and selectively at the dopamine transporter. <i>Bioorganic and Medicinal Chemistry</i> , 2000, 8, 581-590.	3.0	21
70	A Positron Emission Tomography Study Examining The Dopaminergic Activity of Armodafinil in Adults Using [^{11}C]Altropane and [^{11}C]Raclopride. <i>Biological Psychiatry</i> , 2010, 68, 964-970.	1.3	21
71	[^3H]CFT ([^3H]win 35,428) accumulation in dopamine regions of monkey brain: comparison of a mature and an aged monkey. <i>Brain Research</i> , 1993, 611, 322-325.	2.2	20
72	O-526, a piperidine analog of GBR 12909, retains high affinity for the dopamine transporter in monkey caudate-putamen. <i>European Journal of Pharmacology</i> , 1994, 267, 167-173.	2.6	19

#	ARTICLE	IF	CITATIONS
73	Tinkering with THC-to-CBD ratios in Marijuana. <i>Neuropsychopharmacology</i> , 2019, 44, 215-216.	5.4	18
74	Effects of drugs on the metabolism of tryptophan.. <i>Biochemical Pharmacology</i> , 1968, 17, 1037-1047.	4.4	17
75	Effects of daily δ^9 -Tetrahydrocannabinol (THC) alone or combined with cannabidiol (CBD) on cognition-based behavior and activity in adolescent nonhuman primates. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108629.	3.2	17
76	Effects of Skim Milk, Whole Milk and Light Cream on Serum Tryptophan Binding and Brain Tryptophan Concentrations in Rats. <i>Journal of Nutrition</i> , 1975, 105, 1359-1362.	2.9	17
77	Non-amine, drugs without an amine nitrogen, potently block serotonin transport: Novel antidepressant candidates?. <i>Synapse</i> , 2001, 42, 129-140.	1.2	14
78	THC and CBD blood and brain concentrations following daily administration to adolescent primates. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108129.	3.2	14
79	Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. <i>European Journal of Pharmacology</i> , 2003, 479, 41-51.	3.5	13
80	Drug Potencies on Partially Purified Brain D2Dopamine Receptors. <i>Journal of Neurochemistry</i> , 1985, 44, 856-861.	3.9	12
81	11C-WIN 35,428 for detecting dopamine depletion in mild Parkinson's disease. <i>Annals of Neurology</i> , 1994, 35, 376-377.	5.3	12
82	Non-amine dopamine transporter probe [3H]tropoxene distributes to dopamine-rich regions of monkey brain. <i>Synapse</i> , 1999, 34, 20-27.	1.2	12
83	Solubilized receptors for [3H]dopamine (D3 binding sites) from canine brain. <i>Biochemical Pharmacology</i> , 1982, 31, 1183-1187.	4.4	11
84	Concentration of dopamine transporters: To Bmax or not to Bmax?. <i>Synapse</i> , 1999, 32, 136-140.	1.2	11
85	A Second-Generation 99m Tc Single Photon Emission Computed Tomography Agent That Provides in Vivo Images of the Dopamine Transporter in Primate Brain. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3483-3496.	6.4	11
86	Synthesis of 3-(4-heteroaryl-phenyl)-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters. <i>Tetrahedron Letters</i> , 2006, 47, 599-603.	1.4	10
87	Synthesis of 8-thiabicyclo[3.2.1]oct-2-enes and their binding affinity for the dopamine and serotonin transporters. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 6007-6010.	2.2	9
88	Dopamine-transporter density in patients with ADHD. <i>Lancet, The</i> , 2000, 355, 1461-1462.	13.7	8
89	Are THC Levels in Oral Fluids and Blood Plasma Comparable after Oral Ingestion of Edibles Containing Cannabis or THC?. <i>Clinical Chemistry</i> , 2017, 63, 629-631.	3.2	8
90	Solubilized dopamine/neuroleptic receptors (D2-type). <i>Progress in Neuro-Psychopharmacology & Biological Psychiatry</i> , 1981, 5, 543-548.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Synthesis and preliminary characterization of a high-affinity novel radioligand for the dopamine transporter. <i>Synapse</i> , 2001, 39, 175-181.	1.2	7
92	Variants of the primate vesicular monoamine transporter-2. <i>Molecular Brain Research</i> , 2005, 139, 251-257.	2.3	7
93	The Neurobiology of Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2005, 57, 1374-1376.	1.3	7
94	Synthesis of 8-thiabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 1067-1082.	3.0	7
95	Psychiatry and the Opioid Overdose Crisis. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 128-133.	0.8	7
96	Synthesis and biological activity of 2-Carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 4133-4137.	2.2	6
97	Dopamine and norepinephrine transporter-dependent c-Fos production in vitro: relevance to neuroadaptation. <i>Journal of Neuroscience Methods</i> , 2005, 143, 69-78.	2.5	5
98	The synthesis and biological evaluation of 2-(3-methyl or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (3-phenylisoxazol-5-yl)-3-aryl-8-th 2011, 21, 48-51.	2.2	5
99	Molecular and regional targets of cocaine in primate brain: liberation from prosaic views. <i>Addiction Biology</i> , 2000, 5, 351-359.	2.6	4
100	Candidate Performance Measures for Screening for, Assessing, and Treating Unhealthy Substance Use in Hospitals. <i>Annals of Internal Medicine</i> , 2011, 154, 72.	3.9	4
101	Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2762-2772.	3.0	3
102	Dopamine challenge reveals neuroadaptive changes in marijuana abusers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11915-11916.	7.1	3
103	Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 462-462.	2.1	2
104	Growth-associated protein-43 and ephrin B3 induction in the brain of adult SIV-infected rhesus macaques. <i>Journal of NeuroVirology</i> , 2011, 17, 455-468.	2.1	2
105	In memoriam professor Philip Seeman (February 8, 1934-January 9, 2021). <i>Neuropsychopharmacology</i> , 2021, 46, 1229-1230.	5.4	1
106	Drug Use and Its Consequences. , 2014, , 1-35.		1
107	Vesicular Monoamine Transporter 2 Loss in Human Cocaine Abusers Confirmed in Nonhuman Primate Brain. <i>Biological Psychiatry</i> , 2015, 77, 421-422.	1.3	0
108	Ineffective Policies to Address the Opioid Epidemic-Reply. <i>JAMA Psychiatry</i> , 2017, 74, 974.	11.0	0

#	ARTICLE	IF	CITATIONS
109	Cannabinoid and Marijuana Neurobiology. , 2020, , 25-47.		0
110	Cannabis and Medicinal Properties. South Dakota Medicine: the Journal of the South Dakota State Medical Association, 2016, No, 34-45.	0.2	0